

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## CONCORD HEALTHCARE GROUP CO., LTD.

### 美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

## PROPOSED ELECTION OF DIRECTORS OF THE FOURTH SESSION OF THE BOARD

The board (the “**Board**”) of directors (the “**Director(s)**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”) hereby announces that in light of upcoming expiry of the term of the third session of the Board, according to the relevant provisions of the Company Law of the People's Republic of China and the Articles of Association of the Company and the nomination of the nomination committee of the Board (the “**Nomination Committee**”), the Board proposes to nominate the following persons as members of the fourth session of the Board.

### Proposed Directors

### Proposals

Dr. YANG Jianyu	Re-elected to be an executive Director
Ms. FU Xiao	Re-elected to be an executive Director
Mr. CHANG Liang	Re-elected to be an executive Director
Mr. WANG Lei	Re-elected to be a non-executive Director
Mr. SONG Qingbao	Elected to be a non-executive Director
Mr. SHI Botao	Re-elected to be a non-executive Director
Ms. LI Xuemei	Re-elected to be an independent non-executive Director
Mr. SUN Yansheng	Re-elected to be an independent non-executive Director
Mr. NG Kwok Yin	Re-elected to be an independent non-executive Director

According to the Articles of Association of the Company, the proposed election of Directors of the fourth session of the Board shall be subject to the approval of the shareholders of the Company (the “**Shareholders**”) at a general meeting. A circular containing, among others, details regarding the proposed Directors of the fourth session of the Board will be published and/or despatched to the Shareholders in due course. The terms of office of the Directors of the fourth session of the Board will be three years commencing from the date of election at the general meeting of the Company.

Mr. CHEN Hongzhang, the non-executive Director of the third session of the Board, will retire upon the date of the election of Mr. SONG Qingbao at the general meeting of the Company. Mr. CHEN Hongzhang has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders.

Biographical details of the proposed Directors of the fourth session of the Board are set out below:

Dr. YANG Jianyu (楊建宇), aged 54, is our chairman of the Board and executive Director. He is primarily responsible for the overall strategy planning and business development of our Group. Dr. Yang was appointed as a Director of our Company since the establishment of our Company in July 2008, and also served as the general manager of our Company from July 2008 to August 2015. He has also served as a director and general manager of certain of our subsidiaries, including serving as the executive director and general manager of Yinchuan Meizhong Jiahe Internet Hospital Co., Ltd. (銀川美中嘉和互聯網醫院有限公司) since November 2020 and as a director and chairman of the board of Shanghai Concord Medical Cancer Center Co., Ltd. (上海美中嘉和腫瘤門診部有限責任公司), Shanghai Concord Medical Cancer Hospital Limited (上海泰和誠腫瘤醫院有限公司) and Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司) since October 2018, March 2014 and June 2011, respectively.

Dr. Yang has served as the chief executive officer and a director of Concord Medical Services Holdings Limited (a company listed on the New York Stock Exchange (symbol: CCM)) (“**Concord Medical**”) since March 2008, and as the chairman of its board since November 2011. He also serves as a director in the several subsidiaries of Concord Medical, including Beijing Century Friendship Technology Development Co., Ltd. (北京世紀友好科技開發有限公司), Beijing Concord Medical Technology Co., Ltd. (北京泰和誠醫療技術有限公司), Tianjin Concord Medical Technology Co., Ltd. (天津泰和誠醫療技術有限公司) and Shanghai Medstar Financial Leasing Company Limited (醫學之星(上海)融資租賃有限公司) since March 2020, October 2015, April 2010 and October 2009, respectively.

Prior to joining our Group, Dr. Yang served as the president at Eguard Resources Development Co., Ltd. (合加資源發展股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 0826), from January 2003 to January 2007, where he was primarily responsible for its overall management.

Dr. Yang obtained a master’s degree of business administration from Yale University in May 2015, a doctoral degree and a master’s degree in economics from Liaoning University (遼寧大學) in June 1999 and July 1996, respectively. He obtained a bachelor’s degree in economics from Inner Mongolia University of Finance and Economics (內蒙古財經大學) in July 1993. Dr. Yang is a senior economist recognized by Beijing Senior Professional and Technical Position Evaluation Committee (北京市高級專業技術職務評審委員會) in September 2001.

Ms. FU Xiao (付驍), aged 58, is our executive Director, general manager and president. She is primarily responsible for the overall business operation and management of our Group. Ms. Fu joined our Group in April 2009 as a vice president of our Company and was appointed as a Director in April 2020. She has served as the general manager and president of our Company since February 2021 and January 2021, respectively.

Ms. Fu served as the vice president at Shanghai Medstar Financial Leasing Company Limited (醫學之星(上海)融資租賃有限公司) from March 2003 to June 2009. She served as a senior vice president at Concord Medical from July 2009 to March 2019 and as the chief operating officer from March 2019 to January 2021.

Ms. Fu graduated from the nursing school of The Second Military Medical University (第二軍醫大學) in July 1986, and the nursing school of Chinese PLA Postgraduate Medical School (解放軍軍醫進修學院) in October 1993. Ms. Fu also obtained a certificate of completion on EMBA Advanced Seminar on Hospital Management (醫院管理 EMBA 高級研修班) from Peking University in March 2014.

Mr. CHANG Liang (常亮), aged 44, is our executive Director and vice president. He is primarily responsible for the overall management of medical equipment, software and related services of our Group. Mr. Chang joined our Group in June 2009 and has served as our vice president since August 2015. He was appointed as our executive Director in April 2022.

Prior to joining our Group, Mr. Chang worked at German Medtech (Beijing) Co., Ltd. (德邁特醫學技術(北京)有限公司), a company primarily engaged in the development, manufacturing and sale of medical products, from April 2008 to March 2009, and worked at Vaillant (China) Heating and Refrigeration Environmental Technology Co., Ltd. (威能(中國)供熱製冷環境技術有限公司), a company primarily engaged in the manufacturing of heating and air conditioning equipment, from December 2004 to April 2007. He also worked as an auditor at Shanxi Baopeng Certified Public Accountants' Firm (山西寶鵬會計師事務所有限公司) from January 2003 to September 2004.

Mr. Chang obtained a bachelor's degree in accounting from Nankai University (南開大學) in June 2002 and a master's degree in hospital management from Flinders University in Australia in May 2018.

Mr. WANG Lei (王雷), aged 49, is our non-executive Director and vice chairman of the Board. He is primarily responsible for providing guidance and advice on the business strategies of our Group. Mr. Wang was appointed as a Director of our Company in September 2018.

Mr. Wang has served as a managing director at CICC Capital Management Co., Ltd. (中金資本運營有限公司) since March 2019, and successively served as a vice president, an executive director and a managing director at CICC Jia Cheng Investment Management Co., Ltd. (中金佳成投資管理有限公司) from November 2010 to January 2011, from January 2011 to January 2015 and from January 2015 to March 2019, respectively. From December 2009 to November 2010, he also served as the vice general manager at China International Capital Corporation Limited, a company listed on the Shanghai Stock Exchange (stock code: 601995) and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (stock code: 3908). Prior to that, he served as a deputy director at Standard Chartered Private Equity Managers (Hong Kong) Limited (渣打私募股權(香港)有限公司) from April 2009 to December 2009, and as an analyst at investment banking department of China International Capital Corporation Limited from June 2000 to September 2004. Mr. Wang also served as a director at Hangzhou Onechance Tech Co., Ltd. (杭州壹網壹創科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 300792), from February 2017 to April 2021, and as a non-executive director at Freetech Road Recycling Technology (Holdings) Limited (英達公路再生科技(集團)有限公司), a company listed on the Stock Exchange (stock code: 6888), from December 2013 to February 2021.

Mr. Wang obtained a bachelor's degree in international finance from Central University of Finance and Economics (中央財經大學) in July 1999 and a master's degree in business administration from St. Hugh's College, the University of Oxford in September 2005.

Mr. Song Qingbao (宋清寶), aged 41, is currently the executive general manager of CITIC Venture Capital (Shanghai) Co., Ltd. (中信創業投資(上海)有限公司). Mr. Song holds a master's degree and graduated from Peking University in 2008. From 2008 to 2015, he worked at E Fund Management Co., Ltd. (易方達基金管理有限公司); from 2015 to 2018, he worked at Shanghai Lizuo Investment Management Co., Ltd. (上海力作投資管理有限公司); and from 2018 to 2023, he worked at Shanghai Fosun Venture Capital Management Co., Ltd. (上海復星創富投資管理股份有限公司).

Mr. SHI Botao (施波濤), aged 50, is our non-executive Director. He is primarily responsible for the overall management of corporate governance and secretarial matters of our Group. Mr. Shi joined our Group in August 2015 as the board secretary of our Company until August 2024. He was appointed as our executive Director in June 2023 and re-designated as a non-executive Director in August 2024. He has also served as the supervisor at Shanghai Concord Medical Cancer Hospital Limited (上海泰和誠腫瘤醫院有限公司), Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司), Ningbo Jiahe Hospital Management Ltd. (寧波佳和醫院管理有限公司) and Yinchuan Meizhong Jiahe Internet Hospital Co., Ltd. (銀川美中嘉和互聯網醫院有限公司), and a director at Shenzhen Aohua Medical Technology Development Co., Ltd. (深圳傲華醫療科技發展有限公司) and Beijing Yundu Internet Technology Co., Ltd. (北京雲度互聯科技有限公司) since December 2013, April 2011, November 2020, November 2020, January 2018, and April 2018, respectively.

Mr. Shi served as the board secretary and the general manager of asset management department at Concord Medical from October 2007 to July 2015.

Mr. Shi obtained a bachelor's degree in statistics from North China University of Technology (北方工業大學) in July 1998 and a master's degree in business management from Beijing Institute of Technology (北京理工大學) in June 2013.

Ms. LI Xuemei (李雪梅), aged 57, is our independent non-executive Director. She is primarily responsible for supervising and providing independent opinion to our Board.

Ms. Li has been a professor at the School of Economics and Business Administration (經濟與工商管理學院), Chongqing University (重慶大學) since January 2025. Ms. Li has been working in the School of Economics and Management (經濟管理學院) of Beijing Jiaotong University (北京交通大學) since December 1995, and has been a professor since November 2010. She served as an independent non-executive director of CCID Consulting Company Limited (賽迪顧問股份有限公司), a company listed on the Stock Exchange (stock code: 2176), from November 2011 to March 2024. Ms. Li was a visiting scholar at the University of Nevada from August 2014 to December 2014 and a visiting professor at Dartmouth College from December 2014 to August 2015.

Ms. Li obtained a doctoral degree in management from Beijing Jiaotong University in January 2008.

Mr. SUN Yansheng (孫延生), aged 62, is our independent non-executive Director. He is primarily responsible for supervising and providing independent opinion to our Board.

Mr. Sun worked as a member and researcher at planning and development committee of the China Securities Regulatory Commission from February 2013 to April 2016. He also worked as a partner at Beijing Tianyin Law Firm (北京市天銀律師事務所) from December 2002 to March 2013.

Mr. Sun has served as an independent non-executive director of China Shengmu Organic Milk Limited (中國聖牧有機奶業有限公司), a company listed on the Stock Exchange (stock code: 1432) since July 2021. From June 2018 to July 2024, Mr. Sun served as an independent non-executive director of Steve Leung Design Group Ltd. (梁志天設計集團有限公司), a company listed on the Stock Exchange (stock code: 2262). He has also served as an independent director of Mudanjiang Hengfeng Paper Co., Ltd. (牡丹江恒豐紙業股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600356), and as an independent director of Gansu Lanke Petrochemical High-tech Equipment Co., Ltd. (甘肅藍科石化高新裝備股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 601798), since May 2021 and December 2020, respectively. From August 2020 to August 2023, Mr. Sun served as an independent director of Newonder Special Electric Co. Ltd. (新華都特種電氣股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 301120). From September 2017 to June 2022, Mr. Sun served as an independent director of Arctech Solar Holding Co., Ltd. (江蘇中信博新能源科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 688408).

Mr. Sun obtained a bachelor's degree in law from Inner Mongolia University (內蒙古大學) in July 1986. He further obtained a graduate diploma in political economics from Harbin Institute of Technology (哈爾濱工業大學) in May 1999 and a master's degree in law from Renmin University of China in July 2003. Mr. Sun obtained his lawyer license granted by the Ministry of Justice of the PRC in June 1994.

Mr. NG Kwok Yin (吳國賢), aged 50, is our independent non-executive Director. He is primarily responsible for supervising and providing independent opinion to our Board.

Mr. Ng has served as a director and chief financial officer at Zhangmen Education Inc., a company listed on the New York Stock Exchange (symbol: ZME), from November 2020 to July 2021. He also served as a chief financial officer at Meten Edtechx Education Group Ltd., a company listed on the New York Stock Exchange (symbol: METX), from July 2019 to July 2020, and as a chief financial officer at Ming Yang Smart Energy Group Limited (明陽智慧能源集團股份公司), a company listed on the Shanghai Stock Exchange (stock code: 601615), from November 2014 to July 2019. Prior to that, he worked as a senior audit manager at KPMG from October 1999 to August 2012.

Mr. Ng obtained a bachelor's degree in accounting from the Hong Kong University of Science and Technology (香港科技大學) in November 1999. He has been a member of the Hong Kong Institute of Certified Public Accountants since January 2003. He also obtained the board secretary certificate awarded by the Shanghai Stock Exchange in April 2019.

Each of Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin has confirmed that she or he has satisfied the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"). The Company is of the view that Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin are independent persons in accordance with all of the guidelines of independence set out in the Listing Rules.

Upon the election of the Directors of the fourth session of the Board being approved by the Shareholders at the general meeting, the Company will enter into service contracts with such Directors. Their remuneration as Directors will be determined in accordance with the remuneration policy to be approved at the annual general meeting of the Company for the year ended December 31, 2024, the details can be referred to in the annual report to be released by the Company in due course.

As at the date of this announcement, Dr. YANG Jianyu is interested in 205,607,968 domestic shares and 96,518,100 H shares of the Company. Save as disclosed in this announcement, as at the date of this announcement, each of the proposed Directors of the fourth session of the Board:

- (i) has not held any other major appointments or qualifications or directorships in other listed company during the past three years preceding the date of this announcement;
- (ii) does not have any relationship with any Director, supervisor, senior management, substantial or controlling Shareholder (having the meaning ascribed to it in the Listing Rules) of the Company;
- (iii) does not hold other positions with the Company or other members of the Group; and
- (iv) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571).

Save as disclosed in this announcement, there is no further information required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules and there is no other matter relating to the election of Directors of the fourth session of the Board that needs to be brought to the attention of the Stock Exchange or the Shareholders.

By order of the Board  
**Concord Healthcare Group Co., Ltd.**  
**YANG Jianyu**  
*Chairman of the Board and Executive Director*

Beijing, the People's Republic of China, April 13, 2025

*As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. CHEN Hongzhang and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.*